Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

1. A compound of the formula

wherein Ar is selected from the group consisting of aryl, heteroaryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone;

R 1 and R 2 are independently H, alkyl, cycloalkyl, bicyclic alkyl, adamantyl, aralkyl, aryl, R 7 CO, or R 8 OCO;

R 3 is H, alkyl or aralkyl;

X is C;

Y is N;

R 4 is selected from the group consisting of H, alkyl, aralkyl, aryl, heteroaryl, benzoheteroaryl, hydroxyl, halo, haloalkyl, alkoxy, aminocarbonyl and aminosulfonyl;

R 5 and R 6 together form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring;

L 1 is O;

L 2 and L 3 are single bond;

L 4 is (Z) n where each Z is CH 2 ; n is an integer from 1 to 6; and

R 7 and R 8 are independently selected from the group consisting of H, alkyl, aryl and aralkyl, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of the formula:

wherein each R 15 is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of R 15 can form a 5-6 membered aromatic ring or a 5-7 member aliphatic ring;

m is 0-3; and

R 1 , R 2 , R 4 , R 5 , R 6 , n and X are as defined in claim 1 , or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 selected from the group consisting of:

{3-[2-(Benzylmethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

{3-[2-(1-Methyl-1-phenylethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

[3-(2-Benzylaminoethoxy)phenyl]-(2-methylquinolin-4-yl)amine;

[3-(3-Benzylaminopropoxy)phenyl]-(2-methylquinolin-4-yl)amine;

{3-[3-(1-Methyl-1-phenylethylamino)propoxy]phenyl}-(2-methylquinolin-4-yl)amine; and

{3-[3-(adamantan-2-ylamino)propoxy]-5-trifluoromethyl-phenyl}-(2-methylquinolin-4-yl)amine.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.